2025-12-31 - Analysis Report
Okay, here's a comprehensive analysis of Johnson & Johnson (JNJ) based on the provided data, following your instructions:

**1) Return Rate Comparison & Analysis**

*   **Ticker:** JNJ
*   **Company Overview:** Johnson & Johnson is a global healthcare company that researches, develops, manufactures, and sells a broad range of products in the healthcare field.
*   **JNJ Cumulative Return:** 59.46%
*   **S&P 500 (VOO) Cumulative Return:** 102.21%
*   **Divergence:**
    *   Current: -43.2
    *   Max: 16.6
    *   Min: -65.5
    *   Relative Divergence: 27.2

**Analysis:** JNJ has significantly underperformed the S&P 500 over the period examined. The current divergence of -43.2 indicates a substantial difference in cumulative returns. The relative divergence of 27.2 suggests that the current underperformance is closer to the minimum divergence seen historically, meaning JNJ is performing near its worst relative to the S&P 500 within the observed range.

**Alpha, Beta Analysis Table:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 26.0% | 66.8% | -2.0% | -0.1 | 336.6 |
| 2016-2018  | 14.0% | 10.7% | -1.0% | 0.1 | 310.9 |
| 2017-2019  | 20.0% | 71.5% | -2.0% | 0.4 | 351.4 |
| 2018-2020  | 19.0% | 79.2% | -4.0% | 0.4 | 379.2 |
| 2019-2021  | 33.0% | 79.2% | -14.0% | 0.5 | 412.2 |
| 2020-2022  | 8.0% | 79.6% | 9.0% | 0.4 | 425.6 |
| 2021-2023  | -19.0% | 79.6% | -20.0% | 0.3 | 377.6 |
| 2022-2024  | -32.0% | 79.6% | -53.0% | 0.3 | 348.4 |
| 2023-2025  | 31.0% | 79.6% | -36.0% | 0.1 | 498.5 |

**Analysis of Alpha/Beta Table:**

*   **Alpha:** JNJ generally has negative alpha, indicating it has underperformed relative to its risk-adjusted expected return. Noticeable outliers are in 2020-2022 with a positive alpha of 9% while recent years have seen Alpha plummet to -53%. This suggests that there may have been idiosyncratic factors at play within recent history.
*   **Beta:** Beta is consistently low, generally between 0.1 and 0.5, implying lower volatility compared to the market (S&P 500).  This is characteristic of a large, stable company.
*   **CAGR & MDD:** The CAGR (Compound Annual Growth Rate) varies, with some periods showing strong growth and others showing declines. The MDD (Maximum Drawdown) is consistently high, suggesting periods of significant peak-to-trough declines.
*   **Capitalization:** Market cap has grown significantly over the period, indicating overall growth in the company's value, though it fluctuates.

**2) Recent Stock Price Fluctuations**

*   **Close:** 206.91
*   **Last-market:** price: 206.91, previousClose: 207.56, change: -0.31
*   **5-day SMA:** 207.132
*   **20-day SMA:** 206.8395
*   **60-day SMA:** 198.0733

**Analysis:** The stock price is slightly down today (-0.31). The 5-day SMA is slightly above the 20-day SMA, suggesting a very short-term upward trend. However, both are above the 60-day SMA, indicating a stronger, more established upward trend over the past two months.

**3) RSI, PPO, and Expected Return Analysis**

*   **MRI:** 0.9 (Medium Investment Recommended)
*   **RSI:** 61.81
*   **PPO:** -0.35
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent relative divergence change:** -5.7 (short-term decline)
*   **Expected Return:** -65.2%

**Analysis:**

*   The MRI suggests a "Medium Investment Recommended" level of risk.
*   The RSI is at 61.81, suggesting the stock is neither overbought nor oversold.
*   The PPO is slightly negative (-0.35), indicating the short-term moving average is slightly below the long-term moving average, suggesting a very slight downtrend.
*   The Hybrid Signal recommends buying 90% of available cash indicating positive outlook for the stock.
*   The recent decline in relative divergence (-5.7) confirms short-term negative movement versus the S&P 500.
*   The Expected Return of -65.2% is extremely concerning, suggesting a potential for substantial losses if held long-term (more than 2 years).  This is a critical piece of information.

**4) Recent News & Significant Events**

*   **[2025-12-30] JNJ slips after Halda cancer deal closes, Barclays lifts target:** This suggests mixed news. The deal closing may be affecting the stock price in the short term, but Barclays raising the target price is a positive signal.
*   **[2025-12-30] More Upside For JNJ Stock In 2026?:** This suggests that some analysts believe the stock may have better performance in the future.
*   **[2025-12-12] Institutional Investors Are Raising Their Stakes:** This is a positive sign, as it indicates confidence from sophisticated investors.
*   **[2025-12-30] Johnson & Johnson $JNJ Shares Sold by Deprince Race & Zollo Inc.:** This contradicts the previous point and presents a mixed signal.
*   **[2025-12-29] What To Expect From Johnson & Johnson Stock?:** This article likely discusses the outlook for the stock, which is relevant to investors.
*   **[2025-12-30] Johnson & Johnson stock price target raised to $217 from $197 at Barclays:** Further confirms a positive adjustment to analyst outlook.

**Analysis:** The news headlines present a mixed picture. Analyst target price increases and institutional buying are positive, but the stock price slip, sales by some institutions, and uncertainty about future performance create a lack of consensus. The Halda cancer deal seems to be a focus of current market sentiment.

**4-2) Analyst Opinions**

*   **Analyst Consensus:** Buy
*   **Mean:** 2.16 (Buy)
*   **Opinions:** 24
*   **Target Price (avg/high/low):** 210.13 / 240.00 / 155.00
*   **Recent Rating Changes:** Not provided, but needed for full analysis.

**Analysis:** The consensus is "Buy" with a mean rating of 2.16, indicating a generally positive outlook from analysts. The average target price is $210.13, suggesting a potential upside from the current price of $206.91.  The range of target prices is quite wide ($155 to $240), revealing differing opinions on the stock's potential.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-10-22 | 2.14  | 23.99 B$    |
| 2025-07-24 | 2.3   | 23.74 B$    |
| 2025-04-23 | 4.57  | 21.89 B$    |
| 2024-10-23 | 1.12  | 22.47 B$    |
| 2025-10-22 | 1.12  | 22.47 B$    |

**Analysis:**

*   Revenue generally trending upwards over the most recent three quarters (21.89B, 23.74B, 23.99B).
*   EPS is volatile, with a very large spike in 2025-04-23 (4.57) and fluctuating between 1.12, 2.14 and 2.3 in other quarters. This could reflect seasonal factors, one-time gains/losses, or changes in profitability. The duplicate line with 1.12/22.47B needs clarification.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue  | Profit Margin |
|--------------|----------|---------------|
| 2025-09-30   | $23.99B  | 69.56%        |
| 2025-06-30   | $23.74B  | 67.87%        |
| 2025-03-31   | $21.89B  | 66.40%        |
| 2024-12-31   | $22.52B  | 68.35%        |
| 2024-09-30   | $22.47B  | 69.01%        |

**Capital and Profitability:**

| Quarter      | Equity   | ROE   |
|--------------|----------|-------|
| 2025-09-30   | $79.28B  | 6.50% |
| 2025-06-30   | $78.47B  | 7.06% |
| 2025-03-31   | $78.11B  | 14.08% |
| 2024-12-31   | $71.49B  | 4.80% |
| 2024-09-30   | $70.16B  | 3.84% |

**Analysis:**

*   **Revenue & Profit Margin:** Revenue has shown a generally positive trend, and profit margins are consistently high (above 66%), indicating strong profitability.
*   **Equity & ROE:**  Equity has been increasing, reflecting growth in the company's net assets.  ROE (Return on Equity) has fluctuated significantly, with a high in 2025-03-31, but shows an uptrend on the three latest quarters. ROE values represent good returns.

**7) Comprehensive Analysis (Summary)**

Johnson & Johnson (JNJ) presents a mixed investment picture based on the provided data.

**Strengths:**

*   **Strong Financials:** High profit margins, increasing equity, generally positive revenue trend.
*   **Analyst Consensus:** Overall positive analyst sentiment with a "Buy" recommendation and upward revisions in target prices.
*   **Institutional Buying:** Recent buying activity by some institutional investors.
*   **Defensive Stock:** JNJ's lower beta suggests it may be less volatile than the broader market.
* **Medium investment** based on MRI Index.
* **Buy** position based on HybriSignal.

**Weaknesses/Concerns:**

*   **Significant Underperformance:** JNJ has significantly underperformed the S&P 500 over the examined period. The negative divergence is a significant concern.
*   **Negative Alpha:** Consistent negative alpha values indicate underperformance relative to risk-adjusted expectations.
*   **Negative Expected Return:** A VERY concerning -65.2% expected return suggests the potential for substantial losses. This requires further investigation.
*   **Mixed News:** Conflicting news headlines regarding institutional buying/selling and the impact of the Halda cancer deal.
*   **High MDD:** High Maximum Drawdown values indicate significant historical price declines.
*   **Inconsistent EPS:** Volatility in EPS raises questions about earnings consistency.
*   **Recent Relative Divergence Change:** Short-term decline relative to the S&P 500.

**Overall Recommendation (Caveat: Based Solely on Provided Data):**

The negative expected return, historical underperformance, and mixed news headlines raise significant concerns. The positive analyst sentiment and solid financial metrics are encouraging, but they don't outweigh the red flags. I would recommend **extreme caution** before investing in JNJ at this time. Further investigation is needed to understand the drivers of the negative expected return and the reasons for JNJ's underperformance relative to the market. It's also important to understand the full impact of the Halda cancer deal and future plans.

**Disclaimer:** This analysis is based solely on the provided data and should not be considered financial advice.  Consult with a qualified financial advisor before making any investment decisions.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.